Reduction in skin and mucosal toxicity with pegylated liposomal doxorubicin utilizing every 2-week dosing.
Four ovarian cancer patients with severe plantar palmar erythrodysesthesia or mucositis precluding further therapy from pegylated liposomal doxorubicin on the standard every 4 week schedule were able to be treated on every 2-week schedule without recurrence of plantar palmar erythrodysesthesia or stomatitis.